Cargando…
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179940/ https://www.ncbi.nlm.nih.gov/pubmed/33645948 http://dx.doi.org/10.37201/req/019.2021 |
_version_ | 1783703894888546304 |
---|---|
author | Cantón, Rafael Loza, Elena Arcay, Ricardo M. Cercenado, Emilia Castillo, Francisco Javier Cisterna, Ramón Gálvez-Benítez, Lidia Romo, Fernando González Hernández-Cabezas, Alicia Rodríguez-Lozano, Jesús Suárez-Barrenechea, Ana Isabel Tubau, Fe Díaz-Regañón, Jazmín López-Mendoza, Diego |
author_facet | Cantón, Rafael Loza, Elena Arcay, Ricardo M. Cercenado, Emilia Castillo, Francisco Javier Cisterna, Ramón Gálvez-Benítez, Lidia Romo, Fernando González Hernández-Cabezas, Alicia Rodríguez-Lozano, Jesús Suárez-Barrenechea, Ana Isabel Tubau, Fe Díaz-Regañón, Jazmín López-Mendoza, Diego |
author_sort | Cantón, Rafael |
collection | PubMed |
description | OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. METHODS: . The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. RESULTS: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. CONCLUSIONS: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases. |
format | Online Article Text |
id | pubmed-8179940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-81799402021-06-17 Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) Cantón, Rafael Loza, Elena Arcay, Ricardo M. Cercenado, Emilia Castillo, Francisco Javier Cisterna, Ramón Gálvez-Benítez, Lidia Romo, Fernando González Hernández-Cabezas, Alicia Rodríguez-Lozano, Jesús Suárez-Barrenechea, Ana Isabel Tubau, Fe Díaz-Regañón, Jazmín López-Mendoza, Diego Rev Esp Quimioter Original OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. METHODS: . The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. RESULTS: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. CONCLUSIONS: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases. Sociedad Española de Quimioterapia 2021-03-01 2021 /pmc/articles/PMC8179940/ /pubmed/33645948 http://dx.doi.org/10.37201/req/019.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Original Cantón, Rafael Loza, Elena Arcay, Ricardo M. Cercenado, Emilia Castillo, Francisco Javier Cisterna, Ramón Gálvez-Benítez, Lidia Romo, Fernando González Hernández-Cabezas, Alicia Rodríguez-Lozano, Jesús Suárez-Barrenechea, Ana Isabel Tubau, Fe Díaz-Regañón, Jazmín López-Mendoza, Diego Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
title | Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
title_full | Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
title_fullStr | Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
title_full_unstemmed | Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
title_short | Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
title_sort | antimicrobial activity of ceftolozane-tazobactam against enterobacterales and pseudomonas aeruginosa recovered during the study for monitoring antimicrobial resistance trends (smart) program in spain (2016-2018) |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179940/ https://www.ncbi.nlm.nih.gov/pubmed/33645948 http://dx.doi.org/10.37201/req/019.2021 |
work_keys_str_mv | AT cantonrafael antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT lozaelena antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT arcayricardom antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT cercenadoemilia antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT castillofranciscojavier antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT cisternaramon antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT galvezbenitezlidia antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT romofernandogonzalez antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT hernandezcabezasalicia antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT rodriguezlozanojesus antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT suarezbarrenecheaanaisabel antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT tubaufe antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT diazreganonjazmin antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT lopezmendozadiego antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 AT antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018 |